BioCardia, Inc. (NASDAQ:BCDA) Short Interest Down 39.6% in January

BioCardia, Inc. (NASDAQ:BCDAGet Free Report) was the recipient of a large drop in short interest during the month of January. As of January 15th, there was short interest totalling 50,400 shares, a drop of 39.6% from the December 31st total of 83,400 shares. Approximately 1.3% of the shares of the company are sold short. Based on an average daily trading volume, of 48,500 shares, the days-to-cover ratio is presently 1.0 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of BioCardia in a research report on Wednesday, December 18th.

View Our Latest Stock Analysis on BCDA

BioCardia Trading Up 0.4 %

Shares of BCDA opened at $2.28 on Wednesday. BioCardia has a fifty-two week low of $1.63 and a fifty-two week high of $8.85. The firm has a 50-day simple moving average of $2.19 and a 200-day simple moving average of $2.53.

BioCardia Company Profile

(Get Free Report)

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.

Featured Stories

Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.